Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial

Cheol Kyu Park, In Jae Oh, Kyu Sik Kim, Yoo Duk Choi, Tae Won Jang, Youn Seup Kim, Kwan Ho Lee, Kyeong Cheol Shin, Chi Young Jung, Sei Hoon Yang, Jeong Seon Ryu, Seung Hun Jang, Seung Soo Yoo, Suk Joong Yong, Kye Young Lee, Kwang Ho In, Min Ki Lee, Young Chul Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

No prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in nonsquamous non–small-cell lung cancer. A total of 148 chemotherapy-naive patients lacking driver mutations were randomized to the Pem-Cis or Doc-Cis arm. The progression-free survival and response rate was similar between the 2 arms, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm. Introduction To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non–small-cell lung cancer. Materials and Methods A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m2 with either docetaxel 60 mg/m2 (n = 71) or pemetrexed 500 mg/m2 (n = 77) for ≤ 4 cycles. The primary objective was to assess the noninferiority of progression-free survival (PFS) for patients receiving the Doc-Cis regimen. The secondary endpoints were the response rates, overall survival, and toxicity profiles. Results Partial remission was observed in 24 (31.2%) and 24 (33.8%) patients in the Pem-Cis and Doc-Cis groups, respectively. The median PFS was 4.7 months (95% confidence interval [CI], 4.4-5.0) in the Pem-Cis arm and 4.4 months (95% CI, 3.7-5.1) in the Doc-Cis arm (P > .05). The median overall survival was longer in the Doc-Cis arm (13.3 months; 95% CI, 8.1-18.5) than in the Pem-Cis arm (11.7 months; 95% CI, 8.6-14.8; P > .05). Between the 2 arms, no significant difference was found in the subsequent treatments after failure of first-line treatment. The rate of grade 3 or 4 neutropenia and febrile neutropenia was greater in the Doc-Cis arm than in the Pem-Cis arm. Conclusion In nonsquamous non–small-cell lung cancer patients lacking driver mutations, the PFS and response rates were similar between the 2 arms, and toxicity was tolerable, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm.

Original languageEnglish
Pages (from-to)e289-e296
JournalClinical Lung Cancer
Volume18
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

docetaxel
Pemetrexed
Non-Small Cell Lung Carcinoma
Cisplatin
Therapeutics
Disease-Free Survival
Small Cell Lung Carcinoma
Confidence Intervals
Survival Rate

Keywords

  • Chemotherapy
  • Drug toxicity
  • East Asia
  • Progression-free survival
  • Treatment efficacy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer : A TRAIL Trial. / Park, Cheol Kyu; Oh, In Jae; Kim, Kyu Sik; Choi, Yoo Duk; Jang, Tae Won; Kim, Youn Seup; Lee, Kwan Ho; Shin, Kyeong Cheol; Jung, Chi Young; Yang, Sei Hoon; Ryu, Jeong Seon; Jang, Seung Hun; Yoo, Seung Soo; Yong, Suk Joong; Lee, Kye Young; In, Kwang Ho; Lee, Min Ki; Kim, Young Chul.

In: Clinical Lung Cancer, Vol. 18, No. 4, 01.07.2017, p. e289-e296.

Research output: Contribution to journalArticle

Park, CK, Oh, IJ, Kim, KS, Choi, YD, Jang, TW, Kim, YS, Lee, KH, Shin, KC, Jung, CY, Yang, SH, Ryu, JS, Jang, SH, Yoo, SS, Yong, SJ, Lee, KY, In, KH, Lee, MK & Kim, YC 2017, 'Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial', Clinical Lung Cancer, vol. 18, no. 4, pp. e289-e296. https://doi.org/10.1016/j.cllc.2017.01.002
Park, Cheol Kyu ; Oh, In Jae ; Kim, Kyu Sik ; Choi, Yoo Duk ; Jang, Tae Won ; Kim, Youn Seup ; Lee, Kwan Ho ; Shin, Kyeong Cheol ; Jung, Chi Young ; Yang, Sei Hoon ; Ryu, Jeong Seon ; Jang, Seung Hun ; Yoo, Seung Soo ; Yong, Suk Joong ; Lee, Kye Young ; In, Kwang Ho ; Lee, Min Ki ; Kim, Young Chul. / Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer : A TRAIL Trial. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 4. pp. e289-e296.
@article{3bf03121149b4db88b3e82eb80f1340a,
title = "Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial",
abstract = "No prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in nonsquamous non–small-cell lung cancer. A total of 148 chemotherapy-naive patients lacking driver mutations were randomized to the Pem-Cis or Doc-Cis arm. The progression-free survival and response rate was similar between the 2 arms, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm. Introduction To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non–small-cell lung cancer. Materials and Methods A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m2 with either docetaxel 60 mg/m2 (n = 71) or pemetrexed 500 mg/m2 (n = 77) for ≤ 4 cycles. The primary objective was to assess the noninferiority of progression-free survival (PFS) for patients receiving the Doc-Cis regimen. The secondary endpoints were the response rates, overall survival, and toxicity profiles. Results Partial remission was observed in 24 (31.2{\%}) and 24 (33.8{\%}) patients in the Pem-Cis and Doc-Cis groups, respectively. The median PFS was 4.7 months (95{\%} confidence interval [CI], 4.4-5.0) in the Pem-Cis arm and 4.4 months (95{\%} CI, 3.7-5.1) in the Doc-Cis arm (P > .05). The median overall survival was longer in the Doc-Cis arm (13.3 months; 95{\%} CI, 8.1-18.5) than in the Pem-Cis arm (11.7 months; 95{\%} CI, 8.6-14.8; P > .05). Between the 2 arms, no significant difference was found in the subsequent treatments after failure of first-line treatment. The rate of grade 3 or 4 neutropenia and febrile neutropenia was greater in the Doc-Cis arm than in the Pem-Cis arm. Conclusion In nonsquamous non–small-cell lung cancer patients lacking driver mutations, the PFS and response rates were similar between the 2 arms, and toxicity was tolerable, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm.",
keywords = "Chemotherapy, Drug toxicity, East Asia, Progression-free survival, Treatment efficacy",
author = "Park, {Cheol Kyu} and Oh, {In Jae} and Kim, {Kyu Sik} and Choi, {Yoo Duk} and Jang, {Tae Won} and Kim, {Youn Seup} and Lee, {Kwan Ho} and Shin, {Kyeong Cheol} and Jung, {Chi Young} and Yang, {Sei Hoon} and Ryu, {Jeong Seon} and Jang, {Seung Hun} and Yoo, {Seung Soo} and Yong, {Suk Joong} and Lee, {Kye Young} and In, {Kwang Ho} and Lee, {Min Ki} and Kim, {Young Chul}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.cllc.2017.01.002",
language = "English",
volume = "18",
pages = "e289--e296",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer

T2 - A TRAIL Trial

AU - Park, Cheol Kyu

AU - Oh, In Jae

AU - Kim, Kyu Sik

AU - Choi, Yoo Duk

AU - Jang, Tae Won

AU - Kim, Youn Seup

AU - Lee, Kwan Ho

AU - Shin, Kyeong Cheol

AU - Jung, Chi Young

AU - Yang, Sei Hoon

AU - Ryu, Jeong Seon

AU - Jang, Seung Hun

AU - Yoo, Seung Soo

AU - Yong, Suk Joong

AU - Lee, Kye Young

AU - In, Kwang Ho

AU - Lee, Min Ki

AU - Kim, Young Chul

PY - 2017/7/1

Y1 - 2017/7/1

N2 - No prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in nonsquamous non–small-cell lung cancer. A total of 148 chemotherapy-naive patients lacking driver mutations were randomized to the Pem-Cis or Doc-Cis arm. The progression-free survival and response rate was similar between the 2 arms, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm. Introduction To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non–small-cell lung cancer. Materials and Methods A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m2 with either docetaxel 60 mg/m2 (n = 71) or pemetrexed 500 mg/m2 (n = 77) for ≤ 4 cycles. The primary objective was to assess the noninferiority of progression-free survival (PFS) for patients receiving the Doc-Cis regimen. The secondary endpoints were the response rates, overall survival, and toxicity profiles. Results Partial remission was observed in 24 (31.2%) and 24 (33.8%) patients in the Pem-Cis and Doc-Cis groups, respectively. The median PFS was 4.7 months (95% confidence interval [CI], 4.4-5.0) in the Pem-Cis arm and 4.4 months (95% CI, 3.7-5.1) in the Doc-Cis arm (P > .05). The median overall survival was longer in the Doc-Cis arm (13.3 months; 95% CI, 8.1-18.5) than in the Pem-Cis arm (11.7 months; 95% CI, 8.6-14.8; P > .05). Between the 2 arms, no significant difference was found in the subsequent treatments after failure of first-line treatment. The rate of grade 3 or 4 neutropenia and febrile neutropenia was greater in the Doc-Cis arm than in the Pem-Cis arm. Conclusion In nonsquamous non–small-cell lung cancer patients lacking driver mutations, the PFS and response rates were similar between the 2 arms, and toxicity was tolerable, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm.

AB - No prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in nonsquamous non–small-cell lung cancer. A total of 148 chemotherapy-naive patients lacking driver mutations were randomized to the Pem-Cis or Doc-Cis arm. The progression-free survival and response rate was similar between the 2 arms, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm. Introduction To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non–small-cell lung cancer. Materials and Methods A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m2 with either docetaxel 60 mg/m2 (n = 71) or pemetrexed 500 mg/m2 (n = 77) for ≤ 4 cycles. The primary objective was to assess the noninferiority of progression-free survival (PFS) for patients receiving the Doc-Cis regimen. The secondary endpoints were the response rates, overall survival, and toxicity profiles. Results Partial remission was observed in 24 (31.2%) and 24 (33.8%) patients in the Pem-Cis and Doc-Cis groups, respectively. The median PFS was 4.7 months (95% confidence interval [CI], 4.4-5.0) in the Pem-Cis arm and 4.4 months (95% CI, 3.7-5.1) in the Doc-Cis arm (P > .05). The median overall survival was longer in the Doc-Cis arm (13.3 months; 95% CI, 8.1-18.5) than in the Pem-Cis arm (11.7 months; 95% CI, 8.6-14.8; P > .05). Between the 2 arms, no significant difference was found in the subsequent treatments after failure of first-line treatment. The rate of grade 3 or 4 neutropenia and febrile neutropenia was greater in the Doc-Cis arm than in the Pem-Cis arm. Conclusion In nonsquamous non–small-cell lung cancer patients lacking driver mutations, the PFS and response rates were similar between the 2 arms, and toxicity was tolerable, although adverse events and more severe toxicities were observed more frequently in the Doc-Cis arm.

KW - Chemotherapy

KW - Drug toxicity

KW - East Asia

KW - Progression-free survival

KW - Treatment efficacy

UR - http://www.scopus.com/inward/record.url?scp=85011601783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011601783&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2017.01.002

DO - 10.1016/j.cllc.2017.01.002

M3 - Article

C2 - 28185792

AN - SCOPUS:85011601783

VL - 18

SP - e289-e296

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -